SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (655)12/4/2000 5:08:24 PM
From: nigel bates  Read Replies (1) of 666
 
biz.yahoo.com
Dec. 4, 2000--
Integrated Analyses of 251 Patients Treated with Bexxar Shows
Thirty-Five Percent of Patients Achieved Durable Complete Responses
Lasting a Median of More Than Three Years
Coulter Pharmaceutical, Inc. (Nasdaq:CLTR - news) and SmithKline Beecham (NYSE:SBH - news) today announced promising results from a new study of Bexxar(TM) (tositumomab, iodine I 131 tositumomab) in low-grade and transformed low-grade non-Hodgkin's lymphoma (NHL) patients who failed to respond to, or progressed, following rituximab treatment. Bexxar produced a 70 percent overall response rate and a 40 percent complete response rate in patients previously treated with rituximab. Additionally, the companies announced integrated efficacy data on 251 patients treated with Bexxar who had low-grade or transformed low-grade NHL. Data show Bexxar achieved a 35 percent complete response rate lasting a median of more than three years. These results were reported in separate presentations today at the 42nd Annual Meeting and Exposition of the American Society of Hematology in San Francisco, Calif. The Biologics License Application for Bexxar was received by the FDA on September 15, 2000, and is currently under review....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News